<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739687</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0527a</org_study_id>
    <nct_id>NCT00739687</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure</brief_title>
  <acronym>BENEFICIAL</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a&#xD;
      role in the development and progression of heart failure. The AGE-crosslink breaker&#xD;
      Alagebrium improved cardiac function and symptoms in experimental preclinical and small human&#xD;
      heart failure studies. These results have not yet been confirmed in a randomized controlled&#xD;
      clinical trial. Objective: to evaluate the safety and efficacy of alagebrium in subjects&#xD;
      diagnosed with heart failure. This is a randomized, double-blind, placebo-controlled trial to&#xD;
      assess the effects of 400 mg (2 x 100 mg bid) of alagebrium versus placebo over 9 months. 100&#xD;
      subjects will be studied (50 per treatment group) in approximately 6 centers. Procedures:&#xD;
      exercise testing (VO2 max; the primary variable), ECGs and blood sampling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been termination early due to financial constraints.&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point of the study will be aerobic capacity (VO2 max) measured at exercise testing. An improvement of 15% in VO2 max will be considered as a clinically significant increase.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>ALT-711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alagebrium 200 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-711</intervention_name>
    <description>200 mg tablet BID for 9 months.</description>
    <arm_group_label>ALT-711</arm_group_label>
    <other_name>Alagebrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg tablet BID for 9 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NYHA II-IV heart failure&#xD;
&#xD;
          -  Echocardiographic ejection fraction ≤ 45% (echo does not need to be repeated at the&#xD;
             screening visit if a prior echo is on record which indicates an ejection fraction &lt;&#xD;
             40%)&#xD;
&#xD;
          -  Duration of heart failure &gt; 3 months&#xD;
&#xD;
          -  Stable heart failure medical therapy for &gt; 1 month&#xD;
&#xD;
          -  Patients need to be able to understand content of and willing to provide informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient ≤ 18 years&#xD;
&#xD;
          -  History of myocardial infarction in previous 6 months&#xD;
&#xD;
          -  History of stroke/TIA/RIND in previous 6 months&#xD;
&#xD;
          -  Severe valvular dysfunction&#xD;
&#xD;
          -  Severe pulmonary disease&#xD;
&#xD;
          -  History of systemic inflammatory or collagen vascular disease&#xD;
&#xD;
          -  Active and or treated malignancies within 12 months prior to inclusion&#xD;
&#xD;
          -  Any significant condition either medical or non-medical that could lead to difficulty&#xD;
             complying with the protocol&#xD;
&#xD;
          -  Patients on cardiac resynchronisation therapy (CRT) or scheduled for CRT implantation&#xD;
&#xD;
          -  Pacemaker therapy (unless rescue pacing at ≤ 40 bpm) or scheduled pacemaker&#xD;
             implantation&#xD;
&#xD;
          -  History of valve replacement or surgery&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (HbA1c &gt; 9.5%)&#xD;
&#xD;
          -  Clinically significant renal disturbance (sMDRD calculated GFR≤30 mL/min/1.73m2; sMDRD&#xD;
             is calculated as 186 x serum Cr (mg/dl)-1.154 x years-0.203 x (0.742 if female) x&#xD;
             (1.210 if African American)&#xD;
&#xD;
          -  Clinically significant liver disease (ASAT/ALAT &gt; 2,5 times the upper limit of normal)&#xD;
&#xD;
          -  Severe anemia at baseline (Hemoglobin &lt;10 g/dl or &lt;6.2 mmol/l)&#xD;
&#xD;
          -  Use of any investigational drug(s) within 30 days prior to screening&#xD;
&#xD;
          -  Pregnancy or active breast-feeding (urine pregnancy tests will be performed on all&#xD;
             female subjects of childbearing potential)*&#xD;
&#xD;
          -  Active pericarditis/myocarditis&#xD;
&#xD;
          -  The inability of patients to undergo exercise testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Adriaan A. Voors, MD, PhD</name_title>
    <organization>University Medical Center Groningen, Groningen, The Netherlands</organization>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

